Discover what Emgality can do for patients with chronic migraine1

For your patients with ≥15 headache days per month,1

    Quotes

    Having chronic migraine means that at least half my month will be headache days. I need a preventive treatment so I can try to be with my family as much as possible.

    — Hypothetical patient with chronic migraine

    Review study design for REGAIN

    Review safety profile or the results from the 12-month, open-label safety study for Emgality

    References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0120. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0002. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0149. 5. Data on File. Lilly USA, LLC. DOF-GZ-US-0063. 6. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337-1345. 7. Data on File. Lilly USA, LLC. DOF-GZ-US-0057. 8. Data on File. Lilly USA, LLC. DOF-GZ-US-0024. 9. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. 10. Bagley CL, Rendas-Baum R, Maglinte GA, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52:409-421.

    INDICATIONS

    Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

    • Preventive treatment of migraine
    • Treatment of episodic cluster headache

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS
    Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

    WARNINGS AND PRECAUTIONS
    Hypersensitivity Reactions
    Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

    ADVERSE REACTIONS
    The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

    Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

    GZ HCP ISI 10DEC2019